Clinical trials: Platelet Aggregation Inhibitors
Cerebral Infarction
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.
- Trial name
- NCT00386191
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Sanofi
Tinnitus
A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus
1. Overview of tinnitus Tinnitus is a noisy sound which is perceived without any external sound source. According to the survey of the US, 10-20% of adult have the symptom of tinnitus and 3-5% of tinnitus patients have severe…
- Trial name
- CITI-ESR (NCT01378650)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Jong Woo Chung
Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive
Start or STop Anticoagulants Randomised Trial (SoSTART)
Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation…
- Conditions
- Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage, Subdural Hematoma
- Trial name
- SoSTART (NCT03153150)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- 67 sites in United Kingdom
- Volunteers
- 203 people
- Sponsor
- University of Edinburgh
Acute Coronary Syndrome
Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome
The first aim of the study is to prove that after starting the therapy with crushed tablets, the platelet inhibition will be as expected after starting therapy with intact tablets. Gurbel et al.
- Trial name
- ticagrelor (NCT02341729)
- Testing
- ticagrelor
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Platelet Aggregation Inhibitors, Aspirin
GM03 - Platelet RNA Signatures of Aspirin
This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into…
- Conditions
- Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
- Trial name
- NCT05278637
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Duke University
Acute Coronary Syndrome, Platelet Function and Reactivity Tests
Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy
Thus far, no study has evaluated the impact on aspirin in addition to the newer and more potent P2Y12 inhibitors, among ACS patients and current guidelines recommend dual anti-platelet therapy consisting of aspirin and a novel…
- Conditions
- Acute Coronary Syndrome, Platelet Function and Reactivity Tests, Novel P2Y12 Inhibitors
- Trial name
- NCT02049762
- Testing
- Aspirin
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Sheba Medical Center
Pre-diabetes
Resveratrol and First-degree Relatives of Type 2 Diabetic Patients
The main objective of the study is to investigate if resveratrol supplementation can improve overall and muscle-specific insulin sensitivity in first-degree relatives of type 2 diabetic patients.
- Trial name
- NCT02129595
- Testing
- resveratrol
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht University Medical Center
Renal Failure, Coronary Artery Disease
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes)…
- Conditions
- Renal Failure, Coronary Artery Disease, Hemolysis
- Trial name
- NCT03330223
- Testing
- Clopidogrel group;Ticagrelor group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Ischemic Stroke, Antiplatelet Drug
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE）
1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke.
- Trial name
- PATH-STROKE (NCT06269432)
- Testing
- Precision Antiplatelet Therapy Trial Group, Traditional Antiplatelet Therapy Control Group
- Where
- China
- Volunteers
- 1,224 people
- Sponsor
- Sichuan Provincial People's Hospital
Major Haemorrhage
Major Bleeding Risk Associated With Antithrombotics
Prospective, multicenter, observational study with a three-year inclusion period (from January 1, 2012 to December 31, 2015) and a 6-month follow-up
- Trial name
- SACHA (NCT02886533)
- Testing
- Antithrombotic
- Where
- 12 sites in France
- Volunteers
- 6,484 people
- Sponsor
- Rennes University Hospital
Intracranial Aneurysms, Antiplatelet Drugs
Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype
The goal of this clinical trial is to compare the antiplatelet efficacy of aspirin combined with clopidogrel and aspirin combined with half-dose ticagrelor in in patients with unruptured intracranial aneurysms with normal CYP2C19…
- Trial name
- NCT06486363
- Testing
- Aspirin combined with clopidogrel, Aspirin combined with half-dose ticagrelor
- Volunteers
- 196 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Coronary Artery Disease
The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention
The purpose of this study is to examine the effects of tirofiban on platelet function the Ultegra RPFA in diabetic patients undergoing elective coronary angioplasty and stenting already treated with high loading dose (600mg)…
- Trial name
- NCT00407771
- Testing
- Tirofiban
- Where
- Jordan
- Volunteers
- 44 people
- Sponsor
- Jordan Hospital
Coronary Artery Disease, Platelet-aggregation Inhibitors
GLOBAL LEADERS Adjudication Sub-Study
The GLOBAL LEADERS Adjudication Sub-StudY, GLASSY, is based on a re-assessment of all the events reported in the dataset of the parent trial (COMPARATIVE EFFECTIVENESS OF 1 MONTH OF TICAGRELOR PLUS ASPIRIN FOLLOWED BY TICAGRELOR…
- Trial name
- GLASSY (NCT03231059)
- Where
- 19 sites in Austria, Belgium and 7 more
- Volunteers
- 7,365 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Coronary Artery Disease
Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents
It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year.
- Trial name
- NCT00589862
- Testing
- Plavix (Clopidogrel)
- Where
- United States
- Sponsor
- Creighton University
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 872 sites in United States, Australia and 45 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and…
- Trial name
- ACER (NCT07853612)
- Testing
- Apixaban
- Where
- Trinidad and Tobago
- Volunteers
- 16 people
- Sponsor
- The University of The West Indies
Unruptured Intracranial Aneurysm, Stents
Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms
This study was designed to identify high platelet reactivity (HPR) who might have in-stent thrombosis in unruptured aneurysm with intracranial stent placement with light transmittance platelet aggregometry (LTA).
- Conditions
- Unruptured Intracranial Aneurysm, Stents, Antiplatelet Drugs
- Trial name
- APISIA Trail (NCT03989557)
- Testing
- Aspirin and clopidogrel/Ticagrelor, Light transmittance aggregometry
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Beijing Neurosurgical Institute
Atrial Fibrillation, Thrombotic Risk
Regulation of Platelet Function in Older Patients With Atrial Fibrillation
The goal of this observational study is to learn about the effects of antiplatelet drugs on patients over the age of 80 with atrial fibrillation.
- Trial name
- NCT07724301
- Volunteers
- 50 people
- Sponsor
- University of Michigan
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles